IRIDEX Corporation

NasdaqCM IRIX

IRIDEX Corporation Price to Sales Ratio (P/S) on January 14, 2025: 0.55

IRIDEX Corporation Price to Sales Ratio (P/S) is 0.55 on January 14, 2025, a -39.20% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • IRIDEX Corporation 52-week high Price to Sales Ratio (P/S) is 1.15 on April 08, 2024, which is 108.00% above the current Price to Sales Ratio (P/S).
  • IRIDEX Corporation 52-week low Price to Sales Ratio (P/S) is 0.46 on November 07, 2024, which is -17.18% below the current Price to Sales Ratio (P/S).
  • IRIDEX Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 0.72.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
NasdaqCM: IRIX

IRIDEX Corporation

CEO Mr. Patrick Mercer
IPO Date Feb. 16, 1996
Location United States
Headquarters 1212 Terra Bella Avenue
Employees 111
Sector Health Care
Industries
Description

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Similar companies

OFIX

Orthofix Medical Inc.

USD 17.51

0.81%

SSKN

STRATA Skin Sciences, Inc.

USD 2.95

0.00%

TNON

Tenon Medical, Inc.

USD 1.67

-3.47%

AXGN

AxoGen, Inc.

USD 18.24

-0.06%

SRDX

Surmodics, Inc.

USD 35.55

-0.81%

RXST

RxSight, Inc.

USD 30.08

-2.08%

TMCI

Treace Medical Concepts, Inc.

USD 8.01

-4.19%

LUNG

Pulmonx Corporation

USD 6.84

-2.98%

LNSR

LENSAR, Inc.

USD 7.66

-4.96%

NVNO

enVVeno Medical Corporation

USD 3.14

-1.57%

StockViz Staff

January 15, 2025

Any question? Send us an email